Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag China reports positive Phase 3 results for ruxolitinib cream in treating atopic dermatitis, showing strong efficacy and safety.

flag China Medical System reported positive Phase 3 trial results for ruxolitinib cream in treating mild to moderate atopic dermatitis in China, meeting primary and secondary endpoints with significantly higher improvement rates compared to placebo. flag The treatment showed strong efficacy and was well-tolerated, with no serious side effects leading to discontinuation. flag The drug, already approved in the U.S. and Europe, is being advanced for approval in China, with existing access in Hong Kong, Macau, and Guangdong under a regional healthcare initiative. flag It targets a significant unmet need for millions affected by the chronic skin condition.

5 Articles